PURPOSE: Cancer of the ovary confers the worst prognosis among women with gynecological malignancies, primarily because most ovarian cancers are diagnosed at late stage. Hence, there is a substantial need to develop new diagnostic biomarkers to enable detection of ovarian cancer at earlier stages, which would confer better prognosis. In addition, the identification of druggable targets is of substantial interest to find new therapeutic strategies for ovarian cancer. METHODS: The expression of 22,500 genes in a series of 67 serous papillary carcinomas was compared with 9 crudely enriched normal ovarian tissue samples by RNA hybridization on oligonucleotide microarrays. Multiple genes with near-uniformly expression were elevated in carcinomas of varying grade and malignant potential, including several previously described genes (e.g., MUC-1, CD9, CD24, claudin 3, and mesothelin). We performed immunohistochemical staining with antibodies against several of the proteins encoded by differentially expressed genes in an independent cohort of 71 cases of paraffin-embedded ovarian cancer samples. RESULTS: We found striking differences in EpCAM (p < 0.005), CD9 (p < 0.001), MUC-1 (p < 0.001), and claudin 3 proteins (p < 0.001) but not for mesothelin (p > 0.05) using the Mann-Whitney U test. CONCLUSIONS: Protein expression of a majority of the differentially expressed genes tested was found to be elevated in ovarian carcinomas and, as such, define potential new biomarkers or targets.
PURPOSE: Cancer of the ovary confers the worst prognosis among women with gynecological malignancies, primarily because most ovarian cancers are diagnosed at late stage. Hence, there is a substantial need to develop new diagnostic biomarkers to enable detection of ovarian cancer at earlier stages, which would confer better prognosis. In addition, the identification of druggable targets is of substantial interest to find new therapeutic strategies for ovarian cancer. METHODS: The expression of 22,500 genes in a series of 67 serous papillary carcinomas was compared with 9 crudely enriched normal ovarian tissue samples by RNA hybridization on oligonucleotide microarrays. Multiple genes with near-uniformly expression were elevated in carcinomas of varying grade and malignant potential, including several previously described genes (e.g., MUC-1, CD9, CD24, claudin 3, and mesothelin). We performed immunohistochemical staining with antibodies against several of the proteins encoded by differentially expressed genes in an independent cohort of 71 cases of paraffin-embedded ovarian cancer samples. RESULTS: We found striking differences in EpCAM (p < 0.005), CD9 (p < 0.001), MUC-1 (p < 0.001), and claudin 3 proteins (p < 0.001) but not for mesothelin (p > 0.05) using the Mann-Whitney U test. CONCLUSIONS: Protein expression of a majority of the differentially expressed genes tested was found to be elevated in ovarian carcinomas and, as such, define potential new biomarkers or targets.
Authors: Ivo Meinhold-Heerlein; Dirk Bauerschlag; Yingyao Zhou; Lisa M Sapinoso; Keith Ching; Henry Frierson; Karen Bräutigam; Jalid Sehouli; Elmar Stickeler; Dominique Könsgen; Felix Hilpert; Constantin S von Kaisenberg; Jacobus Pfisterer; Thomas Bauknecht; Walter Jonat; Norbert Arnold; Garret M Hampton Journal: Clin Cancer Res Date: 2007-01-15 Impact factor: 12.531
Authors: S Krajewski; M Krajewska; B C Turner; C Pratt; B Howard; J M Zapata; V Frenkel; S Robertson; Y Ionov; H Yamamoto; M Perucho; S Takayama; J C Reed Journal: Endocr Relat Cancer Date: 1999-03 Impact factor: 5.678
Authors: Michael Jäger; Alexandra Schoberth; Peter Ruf; Juergen Hess; Michael Hennig; Barbara Schmalfeldt; Pauline Wimberger; Michael Ströhlein; Bettina Theissen; Markus M Heiss; Horst Lindhofer Journal: Cancer Res Date: 2011-11-01 Impact factor: 12.701
Authors: Raluca A Budiu; Gina Mantia-Smaldone; Esther Elishaev; Tianjiao Chu; Julia Thaller; Kathryn McCabe; Diana Lenzner; Robert P Edwards; Anda M Vlad Journal: Cancer Immunol Immunother Date: 2011-04-02 Impact factor: 6.968
Authors: Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Ronald Simon; Hanspeter Spichtin; Robert Maurer; Urs Metzger; Brida von Castelberg; Rahel Bart; Shanna Stopatschinskaya; Ossi Robert Köchli; Philip Haas; Friedrich Mross; Markus Zuber; Holger Dietrich; Susanne Bischoff; Martina Mirlacher; Guido Sauter; Guenther Gastl Journal: Breast Cancer Res Treat Date: 2004-08 Impact factor: 4.872
Authors: Ranju Ralhan; Jun Cao; Terence Lim; Christina Macmillan; Jeremy L Freeman; Paul G Walfish Journal: BMC Cancer Date: 2010-06-25 Impact factor: 4.430